Compare Stocks

Galiano Gold Inc. engages in the exploration, development, and production of gold properties. It operates and manages the Asanko Gold Mine, which is located in Ghana, West Africa. The company was formerly known as Asanko Gold Inc. and changed its name to Galiano Gold Inc. in May 2020. Galiano Gold Inc. was incorporated in 1999 and is headquartered in Vancouver, Canada.

Barkerville Gold Mines Ltd. engages in the acquisition, exploration, development, and production of gold mineral properties in Canada. The company focuses on the development of Cariboo Mining District of central British Columbia. It controls approximately 195,000 hectares of mineral tenures and Crown-Granted mineral claims, as well as a block of contiguous mineral tenures package centered around the Town of Wells, which is located to the east of Quesnel, British Columbia. The company was formerly known as International Wayside Gold Mines Ltd. and changed its name to Barkerville Gold Mines Ltd. in January 2010. Barkerville Gold Mines Ltd. was incorporated in 1970 and is based in Toronto, Canada.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

PowerShares FTSE RAFI Asia Pacific ex-Japan Portfolio (the Fund) is based on the FTSE RAFI Developed Asia Pacific ex Japan Index (Index). The Fund will normally invest at least 90% of its total assets in securities that comprise the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index is designed to track the performance of the largest equities of companies domiciled in the Asia Pacific region (excluding Japan), selected based on the four fundamental measures of firm size: book value, income, sales and dividends. The 1000 equities with the highest fundamental strength are weighted according to their fundamental scores. The fundamentally weighted portfolio is rebalanced and reconstituted annually. The Fund invests in consumer discretionary, consumer staples, energy, financials, health care, industrials, information technology and telecommunicaiton services sectors. The Fund's investment advisor is Invesco PowerShares Capital Management LLC.